Quarterly report pursuant to Section 13 or 15(d)

Accrued Expenses and Other Liabilities

v3.22.2.2
Accrued Expenses and Other Liabilities
 9 Months Ended
Sep. 30, 2022
Payables and Accruals [Abstract]  
Accrued Expenses and Other Liabilities

Note 7 – Accrued Expenses and Other Liabilities

 

Accrued Expenses, summarized by major category, as of September 30, 2022 and December 31, 2021 consist of the following:

 

    September 30, 2022     December 31, 2021  
Payroll and incentives   $ 1,462     $ 1,343  
Deferred revenue *     1,408       33  
Research and development expenses     334       381  
General and administrative expenses     299       195  
Other deferred liabilities **     194       899  
Total   $ 3,697     $ 2,851  

 

  * At September 30, 2022, the balance included $1,375 thousand related to an exclusive research collaboration with BioNTech SE (the “BioNTech Agreement”) and $33 thousand is related to a feasibility study agreement with Genentech, Inc. (the “Genentech Agreement”), which is expected to be recognized by December 31, 2022. At December 31, 2021, the balance of $33 thousand was related to the Genentech Agreement. The balance of the BioNTech Agreement will be recognized evenly over the next six months. (See Note 9 – Revenue Recognition, Collaboration Agreements and Other).
     
  ** At September 30, 2022 and December 31, 2021, the balances of $194 thousand and $899 thousand, respectively, related to an award agreement with the Cystic Fibrosis Foundation (the “CFF Agreement). (See Note 9 – Revenue Recognition, Collaboration Agreements and Other).